Leaflet: information for the user

PregabalinMABO 25 mg hard capsules EFG

Read this leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you must not give it to others, even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Pregabalina belongs to a group of medications used for the treatment of epilepsy, peripheral and central neuropathic pain, and generalized anxiety disorder (GAD) in adults.

Peripheral and central neuropathic pain:Pregabalina is used for the treatment of chronic pain caused by nerve damage. Various diseases can cause peripheral neuropathic pain, such as diabetes or herpes. The pain sensation could be described as heat, burning, pulsating pain, stabbing pain, acute pain, spasms, continuous pain, tingling, numbness, and pins and needles sensation. Peripheral and central neuropathic pain could also be associated with mood changes, sleep disturbances, fatigue (tiredness), and can affect physical and social activity and overall quality of life.

Epilepsy:Pregabalina is used in the treatment of certain types of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe pregabalina to treat epilepsy when your current treatment does not control the disease. You must take pregabalina in addition to your current treatment. Pregabalina should not be administered alone, but always used in combination with other antiepileptic treatments.

Generalized anxiety disorder:Pregabalina is used in the treatment of generalized anxiety disorder (GAD). Symptoms of GAD include excessive and prolonged anxiety and worry that are difficult to control. GAD can also produce restlessness or feeling of excitement or nervousness, feeling easily fatigued (tired), difficulty concentrating or feeling mentally blank, irritability, muscle tension, or sleep disturbances. This is different from everyday life stress and tensions.

Do not take Pregabalin Mabo:

• If you are allergic to pregabalin or any of the other components of this medication (listed in section 6).

Warnings and precautions:

• Some patients treated with pregabalin have reported symptoms that suggest an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as the appearance of a widespread skin rash. If you experience any of these symptoms, you should seek immediate medical attention.
• Severe skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been associated with pregabalin treatment. Stop taking pregabalin and seek medical attention immediately if you observe any of the symptoms related to these severe skin reactions described in section 4.
• Pregabalin has been associated with dizziness and somnolence, which may increase the risk of accidental injuries (falls) in elderly patients. Therefore, you should exercise caution until you become familiar with the effects of the medication.
• Pregabalin may cause blurred vision, loss of vision, or other changes in vision, many of which are transient. If you experience any alteration in your vision, you should inform your doctor immediately.
• Certain adverse effects, such as somnolence, may be more frequent since patients with spinal cord injury may be taking other medications for treatment, for example, pain or spasticity (tense or rigid muscles), with adverse effects similar to those of pregabalin, so that the intensity of these effects may increase when taken together.
• Patients with diabetes who gain weight while taking pregabalin may need to change their diabetes medications.
• Severe cases of heart failure have been reported in some patients treated with this medication. Most of them were elderly patients with cardiovascular diseases.Before using this medication, you should inform your doctor if you have a history of heart disease.
• Severe cases of kidney failure have been reported in some patients treated with pregabalin. If during treatment with this medication you note a decrease in your ability to urinate, you should inform your doctor since stopping treatment may improve this situation.
• Severe cases of kidney failure have been reported in some patients treated with this medication. If during treatment with pregabalin you note a decrease in your ability to urinate, you should inform your doctor since stopping treatment may improve this situation.
• Some patients taking antiepileptic medications, such as pregabalin, have had thoughts of self-harm or suicide or have shown suicidal behavior. If at any time you experience these thoughts or have shown such behavior, contact your doctor as soon as possible.
• A small number of people taking antiepileptic medications, such as pregabalin, have had thoughts of self-harm or suicide. If at any time you experience these thoughts, contact your doctor as soon as possible.
• When pregabalin is taken with other medications that can cause constipation (such as some types of pain medications), it is possible that gastrointestinal problems (e.g., constipation and intestinal blockage or paralysis) may occur. Inform your doctor if you experience constipation, especially if you are prone to this problem.
• Before taking this medication, inform your doctor if you have ever abused or been dependent on alcohol, prescription medications, or illegal drugs; this may mean that you have a higher risk of becoming dependent on pregabalin.
• Severe cases of seizures have been reported during treatment with pregabalin or shortly after stopping treatment with this medication. If you experience seizures, contact your doctor immediately.
• Severe cases of brain dysfunction (encephalopathy) have been reported in some patients taking pregabalin and who had other serious diseases. Inform your doctor if you have a history of any serious disease, including liver or kidney disease.
• Severe cases of breathing difficulties have been reported. If you have nervous system disorders, respiratory disorders, kidney failure, or are over 65 years old, your doctor may prescribe a different dose. Contact your doctor if you experience breathing problems or shallow breathing.

Dependence

Some people may become dependent on pregabalin (need to continue taking the medication). They may experience withdrawal effects when they stop using pregabalin (see section 3, "How to take Pregabalin" and "If you stop taking pregabalin"). If you are concerned that you may become dependent on Pregabalin, it is essential to consult your doctor.

If you notice any of the following signs while taking pregabalin, it could be a sign that you have become dependent:

• You need to take the medication for a longer time than recommended by your doctor.
• You feel the need to take a higher dose than recommended.
• You are using the medication for reasons other than those prescribed.
• You have made repeated and unsuccessful attempts to stop or control the use of the medication.
• When you stop taking the medication, you experience discomfort and feel better once you take the medication again.

If you notice any of these signs, talk to your doctor to analyze the best care plan for you, including when it is appropriate to stop treatment and how to do it safely.

Children and adolescents:

The safety and efficacy of pregabalin have not been established in children and adolescents (under 18 years) and therefore pregabalin should not be used in this age group.

Use of Pregabalin Mabo with other medications

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.

Pregabalin and certain medications may influence each other (interactions). When pregabalin is used with certain medicationsthat have a sedative effect (including opioids), these effects may be potentiated, and may lead to respiratory failure, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken withother medications that contain.

• Oxycodone – (used as a pain reliever).
• Lorazepam – (used to treat anxiety).
• Alcohol.
• This medication can be taken with oral contraceptives.

Taking Pregabalin Mabo with food, drinks, and alcohol:

• Pregabalin capsules can be taken with or without food.
• It is recommended not to take alcohol during treatment with pregabalin.

Pregnancy, breastfeeding, and fertility

You should not take pregabalin during pregnancy or breastfeeding, unless your doctor has told you to.The use of pregabalin during the first 3 months of pregnancy may cause congenital anomalies in the fetus that require medical treatment. In a study that reviewed data from women in Nordic countries who took pregabalin during the first 3 months of pregnancy, 6 out of 100 babies had such congenital anomalies. This contrasts with 4 out of 100 babies born to women not treated with pregabalin in the study. Congenital anomalies of the face (cleft palate), eyes, nervous system (including the brain), kidneys, and genitals have been reported.

A reliable contraceptive method should be used in women of childbearing age. If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Driving and operating machinery

Pregabalin may cause dizziness, somnolence, and decreased concentration. You should not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medication affects your ability to perform these activities.

Follow exactly the administration instructions of this medication indicated by your doctor.

In case of doubt, consult your doctor or pharmacist again. Do not take more medication than prescribed.

Your doctor will determine the appropriate dose for you.

Pregabalina is exclusively for oral use.

Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:

•Take the number of capsules indicated by your doctor.

•The dose, adjusted for you and your condition, will generally be between 150 mg and 600 mg per day.

•Your doctor will instruct you to take pregabalina two or three times a day. In the case of two times a day, take pregabalina once in the morning and once at night, approximately at the same hour every day. In the case of three times a day, take pregabalina in the morning, at noon, and at night, approximately at the same hour every day.

If you estimate that the action of pregabalina is too strong or too weak, inform your doctor or pharmacist.

If you are an elderly patient (over 65 years old), you should take pregabalina normally, except if you have kidney problems.

Your doctor may prescribe another dosing regimen and/or different doses if you have kidney problems.

Swallow the capsule whole with water.

Continue taking pregabalina until your doctor tells you to stop.

If you take more Pregabalina Mabo than you should

Call your doctor or go to the nearest emergency service immediately. Bring the pregabalina package with you.As a result of taking more pregabalina than you should, you may feel drowsy, confused, agitated, or restless.You may also experience seizures and loss of consciousness (coma).

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.

If you forgot to take Pregabalina Mabo

It is essential to take the pregabalina capsules regularly at the same hour every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose as usual. Do not take a double dose to compensate for the missed doses.

If you interrupt treatment with Pregabalina Mabo

Do not stop taking pregabalina suddenly. If you want to stop taking pregabalina, talk to your doctor first. He will tell you how to do it. If you are going to stop treatment, this should be done gradually over a minimum of one week.

Once the treatment with pregabalina is completed, whether short-term or long-term, you should know that you may experience certain adverse effects, called withdrawal effects. These include sleep problems, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, sweating, and dizziness. These effects may appear more frequently or severely if you have been taking pregabalina for a longer period.

If you experience withdrawal effects, consult your doctor.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

This medication, like all others, may cause side effects, although not everyone will experience them.

Very common: may affect more than 1 in 10 people

• Dizziness, drowsiness, headache.

Common: may affect up to 1 in 10 people

• Increased appetite.
• Euphoria, confusion, disorientation, decreased sexual appetite, irritability.
• Attention alteration, clumsiness of movement, memory deterioration, memory loss, tremors, difficulty speaking, sensation of tingling, numbness, sedation, lethargy, insomnia, fatigue, abnormal sensation.
• Blurred vision, double vision.
• Dizziness, balance problems, falls.
• Dry mouth, constipation, vomiting, flatulence, diarrhea, nausea, swollen abdomen.
• Difficulty with erection.
• Swelling of the body, including extremities.
• Sensation of intoxication, alterations in gait.
• Weight gain.
• Muscle cramps, joint pain, back pain, pain in extremities.
• Throat pain.

Uncommon: may affect up to 1 in 100 people:

• Loss of appetite, weight loss, low blood sugar, high blood sugar.
• Change in self-perception, restlessness, depression, agitation, mood changes, difficulty finding words, hallucinations, strange dreams, anxiety crisis, apathy, aggression, elevated mood, mental deterioration, difficulty thinking, increased sexual appetite, sexual problems, including inability to reach climax, delayed ejaculation.
• Changes in vision, unusual eye movements, changes in vision, including tunnel vision, flashes of light, spasmodic movements, decreased reflexes, hyperactivity, dizziness when standing, sensitive skin, loss of taste, burning sensation, tremors when moving, decreased consciousness, loss of knowledge, fainting, increased sensitivity to sounds, general discomfort.
• Eye dryness, eye swelling, eye pain, tired eyes, watery eyes, eye irritation.
• Changes in heart rhythm, increased heart rate, low blood pressure, high blood pressure, changes in heart rhythm, heart failure.
• Flush, hot flashes.
• Difficulty breathing, dry nose, nasal congestion.
• Increased saliva production, burning sensation, numbness around the mouth.
• Sweating, rash, chills, fever.
• Muscle spasms, joint swelling, muscle stiffness, pain, including muscle pain, neck pain.
• Breast pain.
• Difficulty or pain urinating, inability to hold urine.
• Weakness, thirst, chest oppression.
• Changes in blood test results and liver function tests (elevated creatine phosphokinase in blood, elevated alanine aminotransferase, elevated aspartate aminotransferase, decreased platelet count, neutropenia, elevated creatinine in blood, decreased potassium in blood).
• Hypersensitivity, facial swelling, itching, urticaria, runny nose, nasal bleeding, cough, snoring.
• Menstrual cramps.
• Cold sensation in hands and feet.

Rare: may affect up to 1 in 1,000 people:

• Altered sense of smell, oscillating vision, altered perception of depth, visual brilliance, loss of vision.
• Dilated pupils, strabismus.
• Cold sweat, throat oppression, tongue swelling.
• Pancreatitis.
• Difficulty swallowing.
• Slow or reduced body movement.
• Difficulty writing correctly.
• Fluid accumulation in the abdominal area.
• Liquid in the lungs.
• Convulsions.
• Parkinsonism, Parkinson's disease-like symptoms, such as tremors, bradykinesia (decreased ability to move), and muscle rigidity.
• Changes in the electrocardiogram (ECG) corresponding to heart rhythm alterations.
• Muscle damage.
• Milk secretion, abnormal breast growth, increased breast size in men.
• Menstrual cycle interruption.
• Renal insufficiency, reduced urine output, urinary retention.
• Decreased white blood cell count.
• Inappropriate behavior, suicidal behavior, suicidal thoughts.

Allergic reactions (which may include difficulty breathing, eye inflammation, and a severe skin reaction characterized by flat, non-elevated red patches, or circular or coin-shaped patches on the chest, often with central blisters, skin desquamation, mouth, throat, nose, genital, and eye ulcers. These severe skin reactions may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).

•Jaundice (yellow skin and eyes).

Very rare: may affect up to 1 in 10,000 people

•Liver failure.

•Hepatitis (inflammation of the liver).

Frequency not known: cannot be estimated from available data

•Dependence on pregabalin (“drug dependence”).

Once a short- or long-term treatment with pregabalin is completed, you should know that you may experience certain side effects, called withdrawal effects (see “If you stop taking pregabalin”).

If you experience swelling in the face or tongue, or if your skin becomes red and blisters or peels, seek immediate medical assistance.

Certain side effects, such as drowsiness, may be more frequent since patients with spinal cord injury may be taking other medications to treat, for example, pain or spasticity (tense or rigid muscles), with similar side effects to pregabalin, so the intensity of these side effects may increase when taken together.

The following adverse reaction has been reported in post-marketing experience: difficulty breathing, shallow breathing.

.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the packaging or in the bottle after CAD. The expiration date is the last day of the month indicated.

No special storage conditions are required.

Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.

Composition of Pregabalina Mabo

• The active ingredient is pregabalina. Each hard capsule contains 25 mg of pregabalina.
• The other components are: mannitol (E-421), talc (E-553b), pregelatinized cornstarch, titanium dioxide (E-171), yellow iron oxide (E-172), and gelatin.
• The components of the ink are: Shellac lacquer, black iron oxide (E-172), propylene glycol, strong ammonia solution, and potassium hydroxide (E-525).

Appearance of the product and contents of the packaging

The capsules of this medication are opaque, ivory-colored, and have "25" engraved on them.

PVC/Aluminum blisters containing 56 and 100 (clinical packaging) hard capsules.

Only some packaging sizes may be commercially marketed.

Holder of the marketing authorization and responsible manufacturer

Holder of the marketing authorization

MABO-FARMA, S.A.

Calle Vía de los Poblados, 3, Edificio 6

28033 Madrid,

Spain.

Responsible manufacturer

Pliva Croatia, Ltd.

Prilaz Baruna Filipovica, 25.

10.000, Zagreb, Croatia.

or

Merckle GmbH,

Ludwig-Merckle Strasse, 3.

D-89143, Blauberen-Weiler, Germany

Last review date of this leaflet: January 2024

The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/